tmem237b Antibody

What is TMEM237 and what cellular functions has it been associated with?

TMEM237, also known as ALS2CR4 or JBTS14, belongs to the transmembrane protein family. Current research has revealed several distinct functions of this protein in different cellular contexts. In photoreceptors, TMEM237 localizes exclusively to the outer segment (OS) plasma membrane and is likely involved in membrane trafficking between inner and outer segments of retinal photoreceptors .

In hepatocellular carcinoma, TMEM237 has been shown to play an oncogenic role. It forms a protein complex with NPHP1 and Pyk2, reinforcing Pyk2 phosphorylation and subsequently activating the Pyk2/ERK1/2 pathway . Importantly, TMEM237 is upregulated under hypoxic conditions in HCC cells, with this upregulation being mediated by HIF-1α but not HIF-2α . This hypoxia-induced expression contributes to HCC progression, making TMEM237 a potential therapeutic target for this cancer type.

Mutations in the TMEM237 gene are associated with Joubert syndrome, a rare genetic disorder characterized by brain abnormalities and various developmental issues .

How is TMEM237 expression regulated in normal and pathological states?

In HCC specifically, microarray data (GSE155505) has demonstrated that TMEM237 is significantly upregulated in Hep3B cells under hypoxic conditions . RT-qPCR and Western blotting assays have confirmed that TMEM237 levels dramatically increase under hypoxia, and knockdown of HIF-1α abolishes this effect . Importantly, treatment with DMOG (a PHD inhibitor that mimics hypoxic conditions) notably upregulates both HIF-1α and TMEM237 levels in HCC cells .

In terms of pathological states, TMEM237 is significantly overexpressed in HCC tissues compared to adjacent non-tumor tissues, as demonstrated by analyses of TCGA datasets, GSE76297, and GSE45436 . This overexpression correlates with several clinical parameters in HCC patients, including tumor size, tumor number, TNM stage, and venous infiltration, as shown in the following table:

*P < 0.05, **P < 0.01

What is the subcellular localization pattern of TMEM237?

TMEM237 exhibits specific subcellular localization patterns that are critical to its function. In photoreceptors, immunofluorescent staining of TMEM237 in longitudinal cross-sections of mouse retinas has confirmed that this protein localizes exclusively to the photoreceptor outer segment (OS) . More specifically, when examined in tangential retinal sections cut through the OS layer, TMEM237 staining appears as a ring colocalizing with wheat germ agglutinin, a marker for the OS plasma membrane .

Although some studies have suggested that TMEM237 localization is biased toward the OS base, comprehensive immunostaining has demonstrated its presence throughout the OS plasma membrane . This precise localization is critical for its putative function in membrane trafficking between inner and outer segments of retinal photoreceptors.

For proper detection of TMEM237's subcellular localization, researchers should employ both longitudinal and tangential sections when conducting immunofluorescence studies, as this approach provides a more complete picture of the protein's distribution within specialized cellular compartments.

How does TMEM237 interact with NPHP1 and the Pyk2/ERK pathway in cancer progression?

TMEM237 forms critical protein-protein interactions that drive oncogenic signaling in HCC. Through mass spectrometric analysis of immunoprecipitated protein complexes from HCCLM3 cell lysates, NPHP1 has been identified as a protein interacting with TMEM237 . This interaction has been confirmed through co-immunoprecipitation (co-IP) assays where antibodies against TMEM237 successfully immunoprecipitated NPHP1, and reciprocally, anti-NPHP1 antibodies immunoprecipitated TMEM237 .

The interaction mechanism has been further validated using FLAG-tagged TMEM237 and HA-tagged NPHP1 coexpressed in HEK293T cells, confirming the physical association between exogenous TMEM237 and NPHP1 .

TMEM237 appears to form a tripartite protein complex with NPHP1 and Pyk2, as evidenced by co-IP experiments where antibodies against TMEM237 detected both NPHP1 and Pyk2 in the immunoprecipitates from HCCLM3 lysates . Functionally, TMEM237 enhances the interaction between NPHP1 and Pyk2, with overexpression of TMEM237 strengthening this interaction and knockdown of TMEM237 repressing it .

The downstream consequences of this interaction include increased phosphorylation of Pyk2 and ERK1/2. Specifically, overexpression of TMEM237 increases the phosphorylation levels of Pyk2 and ERK1/2, whereas TMEM237 knockdown notably reduces the activities of these kinases in HCC cells . Importantly, knockdown of NPHP1 counteracts the promotive effects of TMEM237 overexpression on p-Pyk2 and p-ERK1/2 levels, confirming that TMEM237's effects on this signaling pathway are mediated through NPHP1 .

This molecular mechanism explains how TMEM237 contributes to HCC progression, as the Pyk2/ERK1/2 pathway is known to regulate cell proliferation, migration, and invasion in various cancer types.

What are the challenges in developing and validating specific antibodies against TMEM237?

Developing and validating specific antibodies against transmembrane proteins like TMEM237 presents several significant challenges. First, the transmembrane nature of TMEM237 means that portions of the protein are embedded within the lipid bilayer, limiting the accessibility of epitopes for antibody generation. Researchers must carefully select antigenic regions that are exposed (either extracellular or intracellular domains) while avoiding transmembrane domains that tend to be highly hydrophobic and poorly immunogenic.

• Immunoprecipitation followed by mass spectrometry to confirm the identity of the precipitated protein

• Testing in tissues from knockout or knockdown models

• Comparison of staining patterns with multiple antibodies targeting different epitopes of the same protein

• Recombinant expression of tagged proteins for antibody validation

Third, post-translational modifications can affect antibody recognition. TMEM237 may undergo various post-translational modifications that could mask epitopes or create new ones, complicating antibody development and validation.

Finally, the expression level of TMEM237 varies by tissue type and pathological state. As demonstrated in HCC research, TMEM237 is upregulated in tumor tissues compared to adjacent normal tissues , requiring antibodies with sufficient sensitivity to detect both low baseline expression and pathological overexpression.

How can researchers differentiate between splice variants or isoforms of TMEM237 using antibodies?

Differentiating between splice variants or isoforms of TMEM237 requires strategic antibody design and careful experimental planning. Although the provided search results do not specifically mention TMEM237 splice variants, this is a common consideration when studying transmembrane proteins.

To effectively distinguish between TMEM237 isoforms, researchers should:

• Design epitope-specific antibodies targeting unique regions present in only one isoform. This requires thorough bioinformatic analysis of the predicted protein sequences of all known isoforms to identify unique regions.

• Employ isoform-specific primers for RT-qPCR analysis before protein-level studies. For TMEM237, researchers have used specific primers (5′-AGAGCACCATGAGGACTGAC forward and 5′-AGTTGATGGCTCATTGCCCT reverse) for general detection, but isoform-specific primers should target unique exon-exon junctions.

• Use Western blotting with high-resolution gels to separate isoforms based on molecular weight differences. This approach can be particularly effective when isoforms differ significantly in size.

• Perform immunoprecipitation followed by mass spectrometry to identify specific peptides unique to each isoform. This technique provides the highest resolution in distinguishing closely related protein variants.

• Create isoform-specific knockdown or knockout models to validate antibody specificity against each variant. siRNA or CRISPR targeting unique exons can help create these models.

• Consider using targeted proteomics approaches like selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) for quantification of specific isoforms based on unique peptide sequences.

By combining these approaches, researchers can develop a robust strategy to differentiate between potential TMEM237 isoforms and ensure that their experimental findings are properly attributed to the correct protein variant.

What are the optimal techniques for detecting TMEM237 in different experimental systems?

The detection of TMEM237 requires different techniques depending on the experimental system and research question. Based on published methodologies, several approaches have proven effective:

For protein expression analysis in tissues and cells:

• Western blotting has been successfully used to detect TMEM237 protein levels in HCC tissues and cell lines under both normoxic and hypoxic conditions . This technique allows for semi-quantitative assessment of total protein levels.

• Immunohistochemistry (IHC) has proven effective for analyzing TMEM237 expression in paraffin-embedded tissue sections. The protocol involves dewaxing, hydration, heat-induced antigen retrieval, and overnight incubation with primary antibodies at 4°C, followed by incubation with secondary antibodies at room temperature . Staining intensity can be evaluated on a scale of 0-3 and combined with percentage scores to generate comprehensive IHC scores.

• Immunofluorescence microscopy has been used to determine subcellular localization of TMEM237, particularly in retinal tissues. Both longitudinal and tangential retinal sections provide complementary information about TMEM237 distribution .

For mRNA expression analysis:
4. RT-qPCR using SYBR Green Premix PCR Master Mix has been employed with specific primers for TMEM237 (5′-AGAGCACCATGAGGACTGAC forward and 5′-AGTTGATGGCTCATTGCCCT reverse) .

For protein-protein interaction studies:
5. Co-immunoprecipitation (co-IP) assays have successfully demonstrated the interaction between TMEM237 and other proteins such as NPHP1 and Pyk2 . This technique requires careful optimization of lysis conditions to maintain native protein conformations and interactions.

• Mass spectrometry analysis of immunoprecipitated complexes has been used to identify novel interaction partners of TMEM237 .

For functional studies:
7. Overexpression and knockdown approaches, followed by various functional assays, have been employed to study the biological function of TMEM237 in HCC cells and animal models .

The choice of technique should be guided by the specific research question, available resources, and the cellular/tissue system being studied.

What controls are essential when using TMEM237 antibodies in immunohistochemistry and immunofluorescence studies?

When using TMEM237 antibodies for immunohistochemistry (IHC) and immunofluorescence (IF) studies, implementing rigorous controls is essential to ensure reliable and interpretable results. The following controls should be considered mandatory:

• Negative controls:

  • Isotype controls: Use of matched isotype antibodies (e.g., rabbit IgG for rabbit polyclonal anti-TMEM237) to assess non-specific binding

  • Secondary antibody only controls: Omission of primary antibody to evaluate background from secondary antibody

  • Peptide competition/blocking: Pre-incubation of the TMEM237 antibody with the immunizing peptide to confirm specificity

  • Tissue negative controls: Inclusion of tissues known not to express TMEM237 or tissues from TMEM237 knockout models

• Positive controls:

  • Known positive tissues: For TMEM237, photoreceptor outer segments serve as excellent positive controls

  • Overexpression systems: Cells transfected with TMEM237 expression constructs

  • Comparison with mRNA expression: Correlation of protein staining with RT-qPCR results from the same or similar samples

• Validation controls:

  • Multiple antibodies: Use of different antibodies targeting distinct epitopes of TMEM237

  • Knockdown/knockout validation: Demonstration of reduced or absent staining in tissues or cells with TMEM237 knockdown or knockout

  • Correlation with Western blot: Confirmation that IHC/IF results align with Western blot data from the same or similar samples

• Technical controls:

  • Fixation controls: Assessment of different fixation methods to optimize epitope preservation

  • Antigen retrieval optimization: Comparison of different antigen retrieval methods (e.g., heat-induced versus enzymatic)

  • Dilution series: Testing of multiple antibody dilutions to determine optimal signal-to-noise ratio

• Colocalization controls:

  • Dual labeling with known markers: For TMEM237 in photoreceptors, co-staining with wheat germ agglutinin (WGA) can confirm plasma membrane localization

  • Z-stack imaging: Acquisition of multiple focal planes to confirm true colocalization versus overlapping signals

Implementing these controls will significantly enhance the reliability of TMEM237 immunostaining results and facilitate more robust interpretation of experimental data.

How can researchers optimize co-immunoprecipitation protocols to study TMEM237 protein interactions?

Optimizing co-immunoprecipitation (co-IP) protocols for studying TMEM237 protein interactions requires careful consideration of several parameters due to the transmembrane nature of this protein. Based on successful approaches in the literature, researchers should consider the following optimization strategies:

• Cell lysis conditions:

  • Use mild detergents that preserve membrane protein interactions while efficiently extracting TMEM237 from the membrane. Non-ionic detergents like NP-40 or Triton X-100 at 0.5-1% concentration have been effective for TMEM237 .

  • Include protease and phosphatase inhibitor cocktails to prevent degradation and preserve post-translational modifications.

  • Perform lysis at 4°C to minimize protein degradation and maintain interactions.

• Antibody selection and validation:

  • Validate antibody specificity for TMEM237 through Western blotting before attempting co-IP experiments .

  • Consider using antibodies targeting different epitopes of TMEM237 to ensure accessibility in protein complexes.

  • For tagged proteins, commercial antibodies against tags (e.g., FLAG-tagged TMEM237 and HA-tagged NPHP1) have proven effective in co-IP experiments .

• Immunoprecipitation parameters:

  • Optimize antibody concentration and incubation time (typically 1-5 μg of antibody and overnight incubation at 4°C).

  • Include appropriate negative controls, such as isotype-matched IgG, to assess non-specific binding.

  • Consider cross-linking antibodies to beads to avoid heavy and light chain interference in subsequent Western blot analysis.

• Binding and washing conditions:

  • Adjust salt concentration in wash buffers to maintain specific interactions while reducing background (typically 150-300 mM NaCl).

  • Optimize the number and duration of washes to balance between maintaining true interactions and reducing non-specific binding.

  • Consider including low concentrations of detergent in wash buffers to reduce non-specific interactions.

• Elution and detection methods:

  • Use gentle elution conditions to maintain the integrity of co-precipitated proteins.

  • For Western blot detection, optimize transfer conditions for membrane proteins, which may require longer transfer times or different buffer compositions.

  • Consider mass spectrometry analysis of immunoprecipitated complexes to identify novel interaction partners, as successfully applied for TMEM237 .

• Reciprocal co-IP:

  • Perform reciprocal co-IP experiments (e.g., immunoprecipitate with anti-NPHP1 and blot for TMEM237, and vice versa) to strengthen evidence for true interactions .

• Validation in multiple systems:

  • Validate interactions using both endogenous proteins in relevant cell lines and overexpressed proteins in heterologous systems (e.g., HEK293T cells) .

By systematically optimizing these parameters, researchers can develop robust co-IP protocols for studying TMEM237 protein interactions, as demonstrated by the successful identification of the TMEM237-NPHP1-Pyk2 complex in HCC cells .

What are the best approaches for studying TMEM237 function using gene knockdown or knockout models?

Studying TMEM237 function through gene manipulation requires careful experimental design and appropriate model selection. Based on successful approaches in the literature, researchers should consider the following strategies:

• RNA interference (RNAi) approaches:

  • siRNA-mediated knockdown has been successfully used to study TMEM237 function in HCC cell lines . This approach allows for rapid assessment of phenotypes but may have off-target effects and typically achieves only partial knockdown.

  • shRNA-mediated stable knockdown provides more consistent and long-term TMEM237 suppression, which is particularly valuable for in vivo experiments and long-term studies .

  • Ensure validation of knockdown efficiency through both RT-qPCR and Western blotting before proceeding with functional assays.

• CRISPR/Cas9 genome editing:

  • Complete knockout of TMEM237 using CRISPR/Cas9 provides the most definitive approach to studying its function.

  • Design multiple guide RNAs targeting early exons of TMEM237 to ensure functional disruption.

  • For essential genes like TMEM237 that may be required for cell viability, consider inducible CRISPR systems or partial knockouts.

  • Validate knockout at both genomic (sequencing), transcript (RT-qPCR), and protein (Western blot, immunofluorescence) levels.

• Animal models:

  • Rodent models with Tmem67 knockout have shown defects in OS morphology and severe retinal degeneration, suggesting similar approaches could be valuable for studying TMEM237 .

  • Consider conditional knockout models to bypass potential embryonic lethality and study tissue-specific functions.

  • For retinal studies, subretinal injection of viral vectors expressing shRNA against TMEM237 can provide localized knockdown.

• Rescue experiments:

  • Complementation with wild-type TMEM237 in knockdown/knockout models is essential to confirm that observed phenotypes are specifically due to TMEM237 loss.

  • Expression of mutant variants can help identify functional domains, as demonstrated in studies of TMEM237's interaction with NPHP1 and Pyk2 .

• Functional assays:

  • For HCC studies, assess cell proliferation, migration, invasion, and apoptosis in vitro, as well as tumor growth and metastasis in vivo using xenograft models .

  • For photoreceptor studies, evaluate OS morphology, protein trafficking, and visual function using electroretinography.

  • Examine effects on known interacting partners (e.g., NPHP1, Pyk2) and downstream signaling pathways (e.g., ERK1/2) .

• Temporal considerations:

  • Use inducible systems to distinguish between developmental versus maintenance roles of TMEM237.

  • Perform time-course experiments after TMEM237 depletion to identify primary versus secondary effects.

By combining these approaches and carefully validating model systems, researchers can gain comprehensive insights into TMEM237 function in different cellular contexts.